Data / Drug companies / Modavar Pharmaceuticals LLC
Modavar Pharmaceuticals LLC: 59 products in the FDA NDC directory, labeler code 72241
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Modavar Pharmaceuticals LLC (labeler code 72241) lists 59 products in the FDA National Drug Code Directory, covering 20 finished drugs by generic name. By type: 59 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 1, 2025.
The request: Watch Modavar Pharmaceuticals LLC (FDA labeler code 72241): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72241
- Products in commercial distribution
- 59
- Packages
- 178
- Finished drugs by generic name
- 20
- Prescription products
- 59
- Over the counter products
- 0
- Flagged as original packager
- 57 of 57 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- February 5, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 59 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 59 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Olanzapine | 6 | 49 |
| Nebivolol | 4 | 21 |
| Rivastigmine tartrate | 4 | 11 |
| Celecoxib | 4 | 63 |
| Hydralazine hydrochloride | 3 | 47 |
| Telmisartan | 3 | 29 |
| Paroxetine | 3 | 33 |
| Glyburide | 3 | 17 |
| Acyclovir | 3 | 70 |
| Venlafaxine | 3 | 33 |
| Ofloxacin | 3 | 26 |
| Olmesartan medoxomil | 3 | 31 |
| Sildenafil | 3 | 53 |
| Tizanidine hydrochloride | 3 | 25 |
| Fluoxetine | 3 | 42 |
| Bupropion hydrochloride | 2 | 67 |
| Nateglinide | 2 | 9 |
| Erythromycin | 2 | 36 |
| Raloxifene hydrochloride | 1 | 16 |
| Folic acid | 1 | 34 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 22 | 37.3% |
| Capsule | 15 | 25.4% |
| Tablet, film coated | 10 | 16.9% |
| Tablet, coated | 9 | 15.3% |
| Tablet, film coated, extended release | 3 | 5.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Olmesartan Medoxomil | 72241-080 | Tablet, coated | Generic drugs (ANDA) | July 1, 2025 |
| Olmesartan Medoxomil | 72241-079 | Tablet, coated | Generic drugs (ANDA) | July 1, 2025 |
| Olmesartan Medoxomil | 72241-078 | Tablet, coated | Generic drugs (ANDA) | July 1, 2025 |
| Ofloxacin | 72241-074 | Tablet, film coated | Generic drugs (ANDA) | June 24, 2025 |
| Ofloxacin | 72241-073 | Tablet, film coated | Generic drugs (ANDA) | June 24, 2025 |
| Ofloxacin | 72241-072 | Tablet, film coated | Generic drugs (ANDA) | June 24, 2025 |
| Sildenafil | 72241-071 | Tablet, film coated | Generic drugs (ANDA) | February 14, 2024 |
| Sildenafil | 72241-070 | Tablet, film coated | Generic drugs (ANDA) | February 14, 2024 |
| Sildenafil | 72241-069 | Tablet, film coated | Generic drugs (ANDA) | February 14, 2024 |
| Olanzapine | 72241-056 | Tablet | Generic drugs (ANDA) | February 27, 2023 |
| Olanzapine | 72241-055 | Tablet | Generic drugs (ANDA) | February 27, 2023 |
| Olanzapine | 72241-054 | Tablet | Generic drugs (ANDA) | February 27, 2023 |
| Olanzapine | 72241-053 | Tablet | Generic drugs (ANDA) | February 27, 2023 |
| Olanzapine | 72241-052 | Tablet | Generic drugs (ANDA) | February 27, 2023 |
| Olanzapine | 72241-051 | Tablet | Generic drugs (ANDA) | February 27, 2023 |
| Paroxetine | 72241-031 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 20, 2021 |
| Paroxetine | 72241-030 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 20, 2021 |
| Paroxetine | 72241-029 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 20, 2021 |
| Glyburide | 72241-040 | Tablet | Generic drugs (ANDA) | October 5, 2021 |
| Glyburide | 72241-039 | Tablet | Generic drugs (ANDA) | October 5, 2021 |
| Glyburide | 72241-038 | Tablet | Generic drugs (ANDA) | October 5, 2021 |
| Rivastigmine Tartrate | 72241-014 | Capsule | Generic drugs (ANDA) | October 5, 2021 |
| Rivastigmine Tartrate | 72241-013 | Capsule | Generic drugs (ANDA) | October 5, 2021 |
| Rivastigmine Tartrate | 72241-012 | Capsule | Generic drugs (ANDA) | October 5, 2021 |
| Rivastigmine Tartrate | 72241-011 | Capsule | Generic drugs (ANDA) | October 5, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.